Capa » International News (Página 4)

International News

Marchesini Group announces the Beauty Division’s first Open House

19/02/2022 Deixe um comentário

Pianoro (Bologna) – Marchesini Group is opening the doors of its Beauty Division to show the world the latest technologies developed in the field of cosmetic product processing and packaging. From 26 to 30 April, the new 5,000 square metres facilities, recently built inside the Pianoro Headquarters, will host a large selection of machines and production lines developed to meet the needs of the cosmetic industry: from large multinationals to small laboratories, customers and suppliers will be offered an up-close look at technologies designed to cater for the entire production cycle of a cosmetic product, from process to end of line. Leia Mais »

Speaker line-up announced for Frontiers in Gut Microbiome Research digital event

17/02/2022 Deixe um comentário

The panel of speakers at upcoming gut health science digital learning event, ‘Frontiers in Gut Microbiome Research: Application in Nutrition, Health and Wellbeing’ has been revealed by co-hosts Clasado Biosciences (Clasado) and the Quadram Institute. Leia Mais »

AI together with Big Data will be the most disruptive emerging technology duo in the pharmaceutical sector in 2022

10/02/2022 Deixe um comentário

AI together with Big Data will be the most disruptive emerging technology duo in the pharmaceutical sector in 2022, says GlobalData

Despite being years away from exhibiting its full potential, artificial intelligence (AI), together with Big Data, stand out as a versatile combination to address challenges faced by the entire pharmaceutical value chain, says GlobalData, a leading data and analytics company.

In GlobalData’s latest report, ‘The State of the Biopharmaceutical Industry – 2022’, AI, followed by Big Data, were rated by healthcare industry professionals as the top two emerging technologies to have the greatest impact on the pharmaceutical industry in 2022 (rating scale from 1 to 5, where 5 indicated the greatest impact, 1 – minimal impact). This is replicating the same trend seen in the 2021 edition of the report.

Urte Jakimaviciute, Senior Director of Market Research at GlobalData, comments: “AI and Big Data are linked in the healthcare industry. Data derived from numerous pharmaceutical processes can only add value if it is properly analyzed and therefore produces actionable results. As a data-driven algorithm, AI requires high-quality data. The more data AI ingests, the more accurate and efficient it can become. Competence in these tech areas is vital for healthcare companies, as they provide improved patient care at a micro level and, more broadly, drives a higher level of insights and trends that benefit operational and clinical efficiency.”

The growing number of successful AI use cases in the pharmaceutical industry is also contributing to the ever-growing trust in AI. Leading pharma companies forging partnerships in AI include AstraZeneca, GSK, Pfizer, Roche, Janssen, BMS, Merck, Novartis, Takeda, and Bayer.

Jakimaviciute continues: “AI has already shown it can deliver significant productivity improvements and drive efficiencies in drug development processes.”

In January 2020, Exscientia and Sumitomo Dainippon announced the first compound, DSP-1181, designed by AI, to enter a Phase I clinical trial for obsessive compulsive disorder. The project required less than 12 months to complete the exploratory research phase. The second molecule produced by this partnership, DSP-0038, for Alzheimer’s disease psychosis, entered clinical trials in May 2021. In April 2020, BenevolentAI identified Eli Lilly’s baricitinib as a potential COVID-19 treatment in just three days. In April 2021, Exscientia and Evotec announced a Phase I trial for the first AI-designed immuno-oncology drug.

Jakimaviciute adds: “AI in drug discovery has started receiving more and more attention since 2020, with an increasing number of AI-focused vendors, high-value financing rounds, and pharma partnerships. These trends will continue to gather pace and we should witness more of these collaborations in the future.

“Less than one month into 2022 and we have already seen Sanofi sealing a deal with Exscientia to develop oncology and immunology treatments. Further, BenevolentAI and AstraZeneca have agreed on an expansion of their AI-powered drug discovery partnership to include systemic lupus erythematosus and heart failure. This indicates that the role of AI in the drug discovery and development process is only set to grow.”

Drug pricing and reimbursement-related concerns will remain the leading impediment to the pharmaceutical industry’s growth in 2022

09/02/2022 Deixe um comentário

Drug pricing and reimbursement-related concerns will remain the leading impediment to the pharmaceutical industry’s growth in 2022, says GlobalData

Drug pricing pressures will continue to hinder the growth of the pharmaceutical industry in 2022, forcing companies to reassess their pricing strategies and market focus, says GlobalData, a leading data and analytics company. Leia Mais »

Thousands of patients could have rare life-threatening diseases without knowing it, experts warn

07/02/2022 Deixe um comentário

Thousands of patients could unknowingly suffer with a rare life-threatening disease, experts have warned. Leia Mais »

IonsGate Preclinical Services and InSilicoTrials together to innovate drug discovery

03/02/2022 Deixe um comentário

he partnership will allow Canada’s CRO to leverage cutting-edge technology provided

by the European HealthTech company, in order to innovate and optimize

preclinical studies

Canada/Europe, 3 February 2022 – Canadian CRO IonsGate Preclinical Services Inc (IonsGate), that is a market leader in preclinical research services, and European life sciences company InSilicoTrials just announced a partnership to leverage innovative technology like Modeling and Simulation. Leia Mais »

Parkinson’s UK and Domainex collaborate to develop therapies targeting neuroinflammation to slow the progression of Parkinson’s

03/02/2022 Deixe um comentário

London & Cambridge, United Kingdom, 3rd February 2022 / Sciad Newswire / Parkinson’s UK, the largest charitable funder of Parkinson’s research in Europe, and Domainex Ltd., today announce a collaboration focused on developing small molecule therapies targeting neuroinflammation that could slow the progression of Parkinson’s. Domainex, a leading integrated medicines research services partner, will provide fully integrated drug discovery services including assay biology, medicinal and computational chemistry. The collaboration is anticipated to be undertaken over a two-and-a-half-year period, with Parkinson’s UK investing up to £3 million in the project via its drug development arm – the Parkinson’s Virtual Biotech. The innovative programme is plugging the funding gap to fast-track the projects with the greatest scientific potential to transform the lives of people with Parkinson’s. Leia Mais »

Glaucoma market to grow to $3.5 billion by 2030, driven by launch of new pipeline products, says GlobalData

02/02/2022 Deixe um comentário

Steady growth is expected for the glaucoma market across the seven major markets* (7MM) from $2.8 billion in 2020 to $3.5 billion in 2030, at a compound annual growth rate (CAGR) of 2.0%, according to GlobalData. Leia Mais »

Fibre fortification could lower risk of heart disease and diabetes for 7 in 10 UK adults

01/02/2022 Deixe um comentário

01 February 2022 – Increasing the fibre content of everyday UK foods including baked goods, dairy products, soups, smoothies and dressings will enable 50% more adults to get the recommended daily amount of fibre in their diets[1] and lower the risk of heart disease and diabetes for the majority of UK adults, a new study by Tate & Lyle PLC (Tate & Lyle) has found.In a peer reviewed health and nutrition data modelling study* published in the British Journal of Nutrition, scientists from Tate & Lyle, working with specialist data analytics company Crème Global, found that reformulating everyday foods with added fibre could:

Reduce the risk of cardiovascular and type 2 diabetes risk for 72% of the adult population[2]
More than double the number of children in the UK meeting their fibre intake recommendation[3]
See 6% of the UK population lose weight through higher fibre consumption[4]

UK adults consume just 19g of fibre per day on average, significantly under the recommended amount of 30g, with only 9% currently meeting the daily target. Low fibre intake is associated with higher levels of colorectal and breast cancer, cardiovascular disease, and diabetes, and can disrupt the beneficial gut microbiome.Dr Kavita Karnik, Global Head, Nutrition & Regulatory Affairs at Tate & Lyle and a co-author of the health and nutrition data modelling study explains: “Most people understand that eating fibre helps keep bowel function regular, but fewer understand that getting the right amount of fibre in your diet is highly beneficial for wider health and wellbeing, including cardiovascular, immunity, skin, brain and gut health. However, for most people it is difficult to get enough fibre into their diet without exceeding their recommended calorie intake. This is where fibre fortification could play a highly beneficial role to public health – it would allow consumers to continue eating the products they prefer while potentially, lowering rates of cardiovascular disease, Type 2 diabetes and help maintain a healthy weight across the population.”Consumers can take several steps to increase the amount of fibre in their diet:

Swapping jam on toast with almond or other nut butters
Swapping standard yoghurts with added fibre yoghurts
Swapping sugar intake and up fibre intake by swapping the occasional milk chocolate treat with a ‘reduced sugar’ version, with added fibre to retain sweetness without compromising on taste
Swap white sliced breakfast toast with a fibre fortified cereal, marked as ‘source of fibre’ or ‘high in fibre’ on the packet

Tate & Lyle, a leading global provider of food and beverage ingredients and solutions, recently signed up to the UK’s Food and Drink Federation’s Action on Fibre initiative, helping consumers to bridge the gap between fibre intake and the dietary recommendation to help improve gut health and reduce the risk of heart disease, diabetes, and certain types of cancer. Tate & Lyle offers a broad selection of soluble fibre solutions, such as its PROMITOR® fibre, with distinctive attributes for many food and beverage categories. These include sugar and calorie reduction as well as fibre fortification, helping to support healthier lifestyles and provide nutritional benefits, while maintaining great taste.Sara Stanner, Science Director at the British Nutrition Foundation commented: “We know that we need diets to change to support better health but encouraging people to make sustained changes to their behaviour is notoriously difficult. This is where reformulation of the everyday products that people eat and drink can be really effective in improving nutritional intakes. We have seen how reformulation has helped to reduce salt consumption and it’s important that the food industry continues to innovate to produce healthier products, in some cases reducing nutrients such as salt or sugar or by adding beneficial components such as fibre.”Amy Glass, UK Diet and Health Policy Manager, at the Food and Drink Federation commenting on the results of the study: “Reaching the daily recommendation is challenging, even if you eat the recommended 3 portions of starchy food and 5 portions of fruit and vegetables, this still falls short of the daily 30g fibre recommendation. FDF’s Action on Fibre campaign aims to highlight the vital role reformulation and new product development plays for food and beverage companies, giving consumers a wider range of products to assist them in hitting the target more easily. We welcome this research in demonstrating the power these initiatives can have on improving the national diet and raising awareness on the benefits of fibre as part of everyday, healthy lifestyles.”Cronan McNamara, Founder and CEO of Crème Global: “Using mathematical models with real-world dietary data, Crème Global creates scenarios that are a powerful tool with which to assess the potential impacts of various interventions, such as an increase of fibre intake in the UK diet, as demonstrated in this project. We hope the learnings from these scenarios can help inform companies and governments on new product reformulations or public health policies which make a positive impact for citizens.”For more information and tips on how to increase your fibre intake visit: tateandlyle.com/guthealth

*“Estimating the potential public health impact of fibre enrichment: a UK modelling study | British Journal of Nutrition | Cambridge Core”.[1] The age group of 17 years+ getting 30g fibre per day increased by 52.5% (8.0% to 12.2%).[2] The CVD risk distribution curve shifted 13% to the left towards lower CVD risk over the next ten years because of fibre fortification, with 72.2% of subjects achieved a reduction in cardiovascular risk (p ≤ 0.05). A mean of a 5.45% chance of developing type 2 diabetes within the next ten years at baseline was reduced to 4.98% at intervention. A reduction in type 2 diabetes risk was observed in 71.7% of subjects (p ≤ 0.05).[3] The number of children aged 2-5 getting recommended dietary reference values (DRV) 15g/day increased intake by 118.1% (14.9% to 32.5%). The number of children aged 6-10 getting recommend DRV 20g/day increased intake by 111.3% (10.6% to 22.4%). The number of children aged 11-16 getting recommend DRV 25g increased intake by 64.9% (5.7% to 9.4%).[4] Mean body weight reduced by 0.03 kg (from 70.36 kg to 70.33 kg) with 5.9% of subjects achieving a weight reduction (p ≤ 0.05).Notes to EditorsTate & Lyle’s “Estimating the potential public health impact of fibre enrichment: a UK modelling study” looked at what consumers currently eat and drink using the UK’s National Diet and Nutrition Survey. A statistical modelling scenario was applied to see how food that had been reformulated and fortified with additional fibre changed consumer’s diet and health. This included baked goods (for example breads, breakfast cereals, biscuits), beverages, dairy and dairy alternatives, soups, sauces, and dressings. The only change made to the nutritional composition of the products was the addition of fibre. The study identified more than 900 everyday foods that could be enriched with fibre.

Queen’s University Belfast enters collaboration and licensing agreement with Ipsen to progress FLIP inhibitor project which has been supported by Domainex

26/01/2022 Deixe um comentário

Saffron Walden, 26th January 2022 / Sciad Newswire / Domainex Ltd., a leading provider of integrated drug discovery services to life science organisations globally, is delighted that Professors Daniel Longley, Tim Harrison and colleagues at Queen’s University Belfast have entered into a collaboration and licensing agreement with Ipsen. The agreement provides an exclusive licence to research, develop, manufacture and commercialise FLIP inhibitors. Domainex has supported the FLIP inhibitor programme from its inception. Leia Mais »

Página 4 von 11« Primeira...«2 345 6 » 10...Última »